Arcus Biosciences Inc. (RCUS)
NYSE: RCUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
RCUS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.08B
- EPS (TTM)
- -$3.91
- Dividend yield
- None
- 52-week range
- 14.18 – 31.74
- Day range
- 23.90 – 24.83
- Volume / Avg
- 1.60M / 1.32M
- Beta
- —
- Shares outstanding
- 125.77M
- Next earnings
- Oct 27, 2026
52-week range
RCUS stock today
Arcus Biosciences (RCUS) closed at $24.52 on Oct 7, up 0.99% (+$0.24), versus the S&P 500's 0.22% decline. Shares are 22.7% below their 52-week high of $31.74, set on Jun 30, 2026 and 72.9% above the 52-week low of $14.18, in the middle of the past year's range. RCUS is up 3.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 74.9%.
Arcus Biosciences has posted a net loss over the last twelve months (EPS of -$3.91), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Oct 27; analysts expect EPS of -$0.93.
Summary generated from market data by MetaCap's automated system. Methodology
About Arcus Biosciences
Company profileArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Terry J. Rosen Ph.D.
- Headquarters
- Hayward, CA
- Employees
- 601
- IPO year
- 2018
- Website
- arcusbio.com
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$39.91+62.77%
- Strong buy 0
- Buy 11
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 27, 2026
- EPS estimate
- $-0.93
Arcus Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARQTArcutis Biotherapeutics Inc. | 24.17 | +1.05% | $3.04B | vs RCUS |
| ELVNEnliven Therapeutics Inc. | 41.36 | -2.43% | $3.03B | vs RCUS |
| DYNDyne Therapeutics Inc. | 15.97 | +3.70% | $2.98B | vs RCUS |
| ZLABZai Lab Limited ADR | 25.31 | -1.06% | $2.84B | vs RCUS |
| ACADACADIA Pharmaceuticals Inc. | 19.65 | -0.46% | $3.39B | vs RCUS |
| MRVIMaravai LifeSciences Holdings Inc. Class A | 7.43 | -5.35% | $2.75B | vs RCUS |
| AMLXAmylyx Pharmaceuticals Inc. | 27.43 | -2.18% | $3.44B | vs RCUS |
| PGENPrecigen Inc. | 7.54 | -0.13% | $2.70B | vs RCUS |
Indexes, lists and sector
Arcus Biosciences stock FAQ
What is Arcus Biosciences's stock price today?
RCUS last traded at $24.52 as of Oct 7, 4:00 PM EDT, up 0.99% on the day. Prices are delayed at least 15 minutes.
When is Arcus Biosciences's next earnings date?
Arcus Biosciences is expected to report earnings on Tuesday, October 27, 2026. Analysts expect EPS of $-0.93.
Who is Arcus Biosciences's CEO?
Dr. Terry J. Rosen Ph.D. is the chief executive officer of Arcus Biosciences Inc., which has about 601 employees.
What is the RCUS 52-week high?
The 52-week high for RCUS is $31.74 and the 52-week low is $14.18. The stock is currently 22.7% below its high.